Business Wire

ZincFive Unveils BC 2 AI to Power the Next Era of AI-Driven Data Centers

3.11.2025 15:05:00 CET | Business Wire | Press Release

Share

ZincFive®, the world leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced the upcoming release of BC 2 AI, a breakthrough nickel-zinc UPS battery cabinet engineered to meet the unique power demands of artificial intelligence workloads in mission-critical data centers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103566680/en/

Building on the proven performance of ZincFive’s BC Series, BC 2 AI is the industry’s first AI-optimized battery system purpose-built for dual-mode operation. Powered by an advanced Battery Management System and NiZn technology engineered for high AI pulse cycling, it supports both AI dynamic workloads and outage protection within a single, compact footprint. With ultra-fast transient response, exceptional power density, and the superior safety and sustainability of this chemistry, BC 2 AI enables data centers to operate with confidence as AI reshapes infrastructure power demands.

Engineered to absorb sharp transient loads from GPU clusters and AI training environments, BC 2 AI also provides reliable runtime support for traditional IT operations. By managing dynamic power at the UPS level, it eases strain on upstream infrastructure, reduces UPS overdesign, lowers CAPEX, and improves grid interactions. Optimized for both pulse handling and runtime assurance, it delivers simplicity, flexibility, and performance without compromise.

Equipped with a new 90Ah NiZn battery designed for high-intensity discharge cycles, BC 2 AI pairs long service life with a compact, field-upgradable design that adapts as AI power requirements evolve – making it a strategic, future-proof asset for AI-driven data centers.

For hyperscalers, colocation providers, and UPS OEM partners, BC 2 AI delivers AI pulse-ready performance and runtime assurance in the same footprint as traditional IT applications. Competing solutions can require 2 to 4 times more space to meet AI’s power surges (often up to 150% of UPS rated capacity) while BC 2 AI leverages NiZn’s superior power density to deliver required pulse power with minimal footprint expansion. The result is a smarter, more efficient power architecture that lowers upfront CAPEX, reduces lifetime OPEX, and advances data center sustainability goals.

“AI is transforming the very foundation of data centers, creating new challenges that legacy technologies cannot solve,” said Tod Higinbotham, CEO of ZincFive. “With BC 2 AI, we are delivering a safe, sustainable, and future-ready power solution designed to handle the most demanding AI workloads while continuing to support traditional IT backup. This is a defining moment not just for ZincFive, but for the entire data center industry as it adapts to the AI era.”

As ZincFive technology becomes increasingly recognized and deployed worldwide, the company has earned global distinction including TIME’s 2025 World’s and America’s Top GreenTech Companies lists, the 2024 Edison Award™, CleanTech Breakthrough’s 2024 Overall Innovation of the Year, a finalist spot in the 2023 S&P Platts Global Energy Awards, and several other notable industry honors.

About ZincFive, Inc.

ZincFive is the world leader in innovation and delivery of nickel-zinc batteries and immediate power solutions. Supported by an impressive portfolio of international patents, ZincFive technology harnesses The Power of Good Chemistry® to propel the world forward. ZincFive technology leverages the safety and sustainability of nickel-zinc chemistry to provide unparalleled high power density and performance for mission critical applications. ZincFive is a privately held company based in Tualatin, Oregon. For more information, visit www.zincfive.com.

ZincFive and The Power of Good Chemistry are registered trademarks of ZincFive, Inc. and the ZincFive logo is a trademark of ZincFive, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103566680/en/

Contacts

Media Contact:
Ilissa Miller
iMiller Public Relations
Tel: +1.914.315.6424
Email: zincfive@imillerpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye